131results about How to "Avoid induction" patented technology

Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.

The present invention relates to an anode material excellent in its charging and discharging characteristics and a secondary battery excellent in its charging and discharging cyclic characteristics. An anode active material is used for a nonaqueous electrolyte secondary battery including an anode having the anode active material, a cathode having a cathode active material and a nonaqueous electrolyte. The capacity of the anode is expressed by the sum of a capacity component obtained when light metal is doped and dedoped in an ionic state and a capacity component obtained when the light metal is deposited and dissolved. The light metal includes an anode base material capable of doping and dedoping the light metal in an ionic state and a fibrous material having an electric conductivity.

Structures and configurations for planar ultrawideband modular antenna arrays. One example of a PUMA array includes an unbalanced RF interface, a lattice of horizontal dipole segments directly fed with the unbalanced RF interface, the lattice being arranged in either a dual-offset dual-polarized configuration or a single-polarization configuration, and a metallic plate capacitively-coupled to the lattice of horizontal dipole segments and pinned to a ground plane with a first plated via.

Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof:

wherein R₁ and R₂ each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR₁ and —OR₂ each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R₃, R₄, R₅, R₆, R₁₀, R₁₁, R₁₂ and R₁₃ each independently represents a hydrogen, or a lower alkyl; and R₇, R₈ and R₉ each independently represents a hydrogen, —OH, a lower alkoxy, a lower acyloxy, an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof, or any two adjacent groups together may be an alkyene dioxy; with the proviso in certain circumstances that where one of R₇, R₈ and R₉ represents a hydrogen, then —OR₁, —OR₂ and the other two of R₇, R₈ and R₉ do not simultaneously represent —OH.

A printed circuit board integrated with a two-axis fluxgate sensor includes a first soft magnetic core formed lengthwise in a first axial direction, a first excitation coil formed of a metal film and wound around the first soft magnetic core, a first pick-up coil formed of a metal film and wound around the first soft magnetic core and the first excitation coil, a second soft magnetic core formed lengthwise in a second axial direction, the second axial direction being perpendicular to the first axial direction, a second excitation coil formed of a metal film and wound around the second soft magnetic core, a second pick-up coil formed of a metal film and wound around the second soft magnetic core and the second excitation coil, and a pad for establishing conductivity between the first and second excitation coils and the first and second pick-up coils and an external circuit.

In a fluxgate sensor integrated in a semiconductor substrate and a method for manufacturing the same, the fluxgate sensor includes a soft magnetic core formed on the semiconductor substrate, an excitation coil winding the soft magnetic core and being insulated by first and second insulating layers deposited above and below the soft magnetic core, respectively, and a pick-up coil, winding the soft magnetic core and being insulated by third and fourth insulating layers deposited above and below the excitation coil, respectively.

A substrate holding device for clamping a substrate in a processing chamber in which plasma processing is carried out includes a chuck main body having positive and negative electrodes and, a chuck plate having a rib portion capable of bringing the peripheral edge portion of the substrate into surface contact therewith and multiple support portions provided upright and arranged at predetermined intervals in an internal space surrounded by the rib portion, a DC power supply for applying a DC voltage between the two electrodes, an AC power supply for passing an alternating current through the capacitance of the chuck plate, and first measuring means for measuring the alternating current passing through the capacitance of the chuck plate, and further includes removing means for removing an AC component superimposed on the alternating current from a plasma produced in the processing chamber during plasma processing.

The present invention relates to the treatment of dopamine-related dysfunction using full D₁ dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The D₁ agonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates D₁ dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full D₁ agonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating D₁ dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of D₁ dopamine receptors for a period of time sufficient to prevent induction of tolerance.

The present invention describes a method to detect connective tissue pathologies associated with Graves' disease ophthalmopathy and other antibody mediated inflammatory autoimmune diseases. The detection method comprises obtaining a sample from a patient suffering from an antibody-mediated inflammatory autoimmune disorder and measuring Interleukin 16 (IL-16) or RANTES produced by thyroid associated ophthalmopathy fibroblasts to indicate the presence or severity.

The present invention relates to compositions comprising extracts of Durio zibethinus. The compositions of the present invention are useful for improving the appearance, texture, and/or moisture of mammalian skin. In particular, the compositions of the present invention decrease inflammation in the skin, inhibit matrix metalloprotease-9, which degrades skin proteins such as collagen and elastin, and inhibit melanogenesis in the skin.

A method for promoting auto-induction of transcription of cloned DNA in cultures of bacterial cells grown batchwise is disclosed. The transcription is under the control of a promoter whose activity can be induced by an exogenous inducer whose ability to induce said promoter is dependent on the metabolic state of said bacterial cells. Initially, a culture media is provided which includes: i) an inducer that causes induction of transcription from said promoter in said bacterial cells; and ii) a metabolite that prevents induction by said inducer, the concentration of said metabolite being adjusted so as to substantially preclude induction by said inducer in the early stages of growth of the bacterial culture, but such that said metabolite is depleted to a level that allows induction by said inducer at a later stage of growth. The culture medium is inoculated with a bacterial inoculum, the inoculum comprising bacterial cells containing cloned DNA, the transcription of which is induced by said inducer. The culture is then incubated under conditions appropriate for growth of the bacterial cells. Also disclosed is a method for improving the production of a selenomethionine-containing protein or polypeptide in a bacterial cell, the protein or polypeptide being produced by recombinant DNA techniques, the bacterial cell encoding a vitamin B12-dependent homocysteine methylase. The method for improving the production of this protein or polypeptide includes culturing the bacterial cell in a culture medium containing vitamin B12. Finally, disclosed is a method for suppressing transcription of cloned DNA in cultures of bacterial cells grown batchwise, said transcription being under the control of a promoter whose activity can be induced by an exogenous inducer whose ability to induce said promoter is dependent on the metabolic state of said bacterial cells.

The invention provides a thermal field structure for growing large-sized silicon carbide monocrystal. The structure integrally comprises a crucible, a crucible cover, a seed crystal rod, an upper insulating layer structure, a lower insulating layer structure, a lateral insulating layer structure and an induction coil, wherein the crucible is divided into a cylindrical bottomless structure and a crucible support, the cylindrical bottomless structure is put on the crucible support and is made of a high-purity graphite material, and the crucible support is made of a high-temperature-resistance insulating material; the lower end of the seed crystal rod has a seed crystal tray structure, and is moved along with height reduction of a solid raw material in the sublimating process; the induction coil structure outside the lateral insulating layer structure can be moved downwards from top, so that a reasonable interval between a growing interface of crystal and a raw material can be ensured. The thermal field structure can be used for reducing the probability of crystal fracture and effectively reducing the defects of micropipe, stress and the like inside the crystal, and realizes the growth of large-sized half-insulating silicon carbide monocrystal.

The present invention provides methods for modulating an immune response by administering a composition comprising a Toll-like receptor agonist and an immune mediator which downregufates the expression of the anti-inflammatory cytokine IL-10 and upregulates the expression of the pro-inflammatory cytokine IL-12. The methods can be used to provide therapeutic treatment for cancerous conditions and infectious diseases.